AJP - Heart AJP: Endocrinology and Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 277: H228-H235, 1999;
0363-6135/99 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thourani, V. H.
Right arrow Articles by Vinten-Johansen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thourani, V. H.
Right arrow Articles by Vinten-Johansen, J.
Vol. 277, Issue 1, H228-H235, July 1999

Adenosine A3-receptor stimulation attenuates postischemic dysfunction through KATP channels

Vinod H. Thourani1, Masanori Nakamura1, Russell S. Ronson1, James E. Jordan1, Zhi-Qing Zhao1, Jerrold H. Levy2, Fania Szlam2, Robert A. Guyton1, and Jakob Vinten-Johansen1

1 Division of Cardiothoracic Surgery, Department of Surgery, 2 Department of Anesthesiology, Emory University School of Medicine, Carlyle Fraser Heart Center-Cardiothoracic Research Laboratory, Crawford Long Hospital, Atlanta, Georgia 30365-2225

We tested the hypothesis that selective adenosine A3-receptor stimulation reduces postischemic contractile dysfunction through activation of ATP-sensitive potassium (KATP) channels. Isolated, buffer-perfused rat hearts (n = 8/group) were not drug pretreated (control) or were pretreated with adenosine (20 µM), 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (Cl-IB-MECA; A3 agonist, 100 nM), Cl-IB-MECA + 8-(3-noradamantyl)-1,3-dipropylxanthine (KW-3902; A1 antagonist, 5 µM), Cl-IB-MECA + glibenclamide (Glib; KATP-channel blocker, 0.3 µM), or Glib alone for 12 min before 30 min of global normothermic ischemia followed by 2 h of reperfusion. After 2 h of reperfusion, left ventricular developed pressure (LVDP, %baseline) in control hearts was depressed to 34 ± 2%. In hearts pretreated with Cl-IB-MECA, there was a statistically significant increase in LVDP (50 ± 6%), which was reversed with coadministration of Glib (37 ± 1%). Control hearts also showed similar decreases in left ventricular peak positive rate of change in pressure (dP/dt). Therefore, the A3 agonist significantly attenuated postischemic cardiodynamic injury compared with the control, which was reversed by Glib. Cumulative creatine kinase (CK in U/min) activity was most pronounced in the control group (10.4 ± 0.6) and was significantly decreased by Cl-IB-MECA (7.5 ± 0.4), which was reversed by coadministration of Glib (9.4 ± 0.2). Coronary flow was increased during adenosine infusion (160% of baseline) but not during Cl-IB-MECA infusion. Effects of Cl-IB-MECA were not reversed by the specific A1 antagonist KW-3902. We conclude that cardioprotection afforded by A3-receptor stimulation may be mediated in part by KATP channels. Cl-IB-MECA may be an effective pretreatment agent that attenuates postischemic cardiodynamic dysfunction and CK release without the vasodilator liability of other adenosine agonists.

myocardial protection; purinergic receptors; rat; adenosine 5'-triphosphate-sensitive potassium channels


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
T. C. Wan, Z.-D. Ge, A. Tampo, Y. Mio, M. W. Bienengraeber, W. R. Tracey, G. J. Gross, W.-M. Kwok, and J. A. Auchampach
The A3 Adenosine Receptor Agonist CP-532,903 [N6-(2,5-Dichlorobenzyl)-3'-aminoadenosine-5'-N-methylcarboxamide] Protects against Myocardial Ischemia/Reperfusion Injury via the Sarcolemmal ATP-Sensitive Potassium Channel
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 234 - 243.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
V. Shneyvays, D. Leshem, T. Zinman, L. K. Mamedova, K. A. Jacobson, and A. Shainberg
Role of adenosine A1 and A3 receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury
Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2792 - H2801.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
L. Willems, K. J. Ashton, and J. P. Headrick
Adenosine-mediated cardioprotection in the aging myocardium
Cardiovasc Res, May 1, 2005; 66(2): 245 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Headrick, B. Hack, and K. J. Ashton
Acute adenosinergic cardioprotection in ischemic-reperfused hearts
Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H1797 - H1818.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. A. Auchampach, Z.-D. Ge, T. C. Wan, J. Moore, and G. J. Gross
A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs
Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H607 - H613.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Kennergren, V. Mantovani, L. Strindberg, E. Berglin, A. Hamberger, and P. Lonnroth
Myocardial interstitial glucose and lactate before, during, and after cardioplegic heart arrest
Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E788 - E794.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
G. J Harrison, R. J Cerniway, J. Peart, S. S Berr, K. Ashton, S. Regan, G Paul Matherne, and J. P Headrick
Effects of A3 adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart
Cardiovasc Res, January 1, 2002; 53(1): 147 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
R. J. Cerniway, Z. Yang, M. A. Jacobson, J. Linden, and G. P. Matherne
Targeted deletion of A3 adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium
Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1751 - H1758.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
E. L. Kilpatrick, P. Narayan, R. M. Mentzer Jr., and R. D. Lasley
Adenosine A3 agonist cardioprotection in isolated rat and rabbit hearts is blocked by the A1 antagonist DPCPX
Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H847 - H853.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
R. D. Lasley, M. S. Jahania, and R. M. Mentzer Jr.
Beneficial effects of adenosine A2a agonist CGS-21680 in infarcted and stunned porcine myocardium
Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1660 - H1666.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. Peart and J. P. Headrick
Intrinsic A1 adenosine receptor activation during ischemia or reperfusion improves recovery in mouse hearts
Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2166 - H2175.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. P. Headrick, N. S. Gauthier, R. Morrison, and G. P. Matherne
Cardioprotection by KATP channels in wild-type hearts and hearts overexpressing A1-adenosine receptors
Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1690 - H1697.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online